Beyfortus market gains as RSV prevention demand rises

The Business Research Company says the Beyfortus market is expanding as health systems seek better RSV prevention for newborns and infants. The report points to higher RSV burden, continued R&D, and strong North America demand, with Asia-Pacific expected to grow fastest.

Why it matters: - Beyfortus demand is tied to the global push to prevent respiratory syncytial virus, or RSV, in newborns and infants. - The market reflects broader spending on neonatal protection, passive immunization, and longer-acting preventive tools. - Rising RSV cases make prevention more important for hospitals, public health systems, and families with high-risk children.

What happened: - The Business Research Company released its Beyfortus Global Market Report 2026, covering market size, trends, and forecasts for 2026-2035. - The report says the Beyfortus market has grown in recent years because of infant RSV hospitalizations, monoclonal antibody progress, better neonatal care, and regulatory approvals. - The report says Beyfortus is scientifically known as nirsevimab. - Beyfortus is designed to give passive immunity against RSV with a single dose that provides extended protection. - Beyfortus is primarily used to protect newborns and infants during their first RSV season from severe lower respiratory tract infections. - The report includes analysis of Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The details: - The report says future growth will be driven by newborn protection programs, higher RSV awareness, increased health funding, broader clinical guidelines, and innovation in long-acting antibodies. - Key market trends include passive immunization strategies, RSV prevention in infants, single-dose long-acting antibodies, hospital-based neonatal protection, and seasonal RSV preparedness. - The report says rising RSV infections are a major growth driver because RSV can cause bronchiolitis and pneumonia and affects infants, young children, older adults, and immunocompromised people. - The report links the surge in RSV cases to reduced herd immunity in populations. - The World Health Organization reported in March 2025 that RSV causes about 3.6 million hospitalizations and 100,000 deaths a year among children under 5. - The report says R&D activity is supporting market growth by improving the safety, efficacy, and accessibility of RSV prevention tools. - Eurostat reported that the European Union’s government R&D budget reached about €127,916 million in 2024, up 3.4% from €123,675 million in 2023. - In 2025, North America held the largest share of the Beyfortus market because of mature healthcare infrastructure, broad awareness, and regulatory support. - Asia-Pacific is expected to be the fastest-growing region because of higher healthcare investment, expanding newborn care programs, and rising RSV awareness. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, and updated charts. - The report offers a free sample at the sample report. - The full report is available at the full market report.

Between the lines: - The market outlook suggests Beyfortus is moving from a niche preventive option to a more central RSV tool for infant care. - The regional split points to a mature adoption story in North America and a growth runway in Asia-Pacific. - The emphasis on long-acting, single-dose protection suggests buyers want simpler prevention programs that fit hospital and seasonal workflows.

What's next: - The report expects the market to keep expanding as RSV prevention programs broaden and more guidelines support use in infants. - Adoption will likely track seasonal RSV planning, healthcare funding, and the rollout of newborn protection programs. - Further market shifts will depend on continued R&D, regulatory support, and health system willingness to scale passive immunization approaches.

The bottom line: - Beyfortus is benefiting from a stronger global focus on RSV prevention, and the market outlook points to continued growth led by infant protection demand and expanding regional adoption.